Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS; Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators.

J Clin Oncol. 2019 Dec 1;37(34):3192-3202. doi: 10.1200/JCO.19.00915. Epub 2019 Sep 25.

PMID:
31553693
2.

Biological Parts for Kluyveromyces marxianus Synthetic Biology.

Rajkumar AS, Varela JA, Juergens H, Daran JG, Morrissey JP.

Front Bioeng Biotechnol. 2019 May 7;7:97. doi: 10.3389/fbioe.2019.00097. eCollection 2019.

3.

The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma.

Haveman LM, Ranft A, Vd Berg H, Smets A, Kruseova J, Ladenstein R, Brichard B, Paulussen M, Kuehne T, Juergens H, Klco-Brosius S, Dirksen U, Merks JHM.

Cancer Med. 2019 Mar;8(3):1086-1094. doi: 10.1002/cam4.2002. Epub 2019 Feb 21.

4.

Evaluation of a novel cloud-based software platform for structured experiment design and linked data analytics.

Juergens H, Niemeijer M, Jennings-Antipov LD, Mans R, Morel J, van Maris AJA, Pronk JT, Gardner TS.

Sci Data. 2018 Oct 3;5:180195. doi: 10.1038/sdata.2018.195.

5.

Impact of Whole Lung Irradiation on Survival Outcome in Patients With Lung Relapsed Ewing Sarcoma.

Scobioala S, Ranft A, Wolters H, Jabar S, Paulussen M, Timmermann B, Juergens H, Hassenpflug W, Klingebiel T, Elsayad K, Eich HT, Dirksen U.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):584-592. doi: 10.1016/j.ijrobp.2018.06.032. Epub 2018 Jul 3.

PMID:
30244879
6.

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O; Euro-E.W.I.N.G.99 and EWING-2008 Investigators.

J Clin Oncol. 2018 Sep 6:JCO2018782516. doi: 10.1200/JCO.2018.78.2516. [Epub ahead of print]

7.

Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy.

Kreyer J, Ranft A, Timmermann B, Juergens H, Jung S, Wiebe K, Boelling T, Schuck A, Vieth V, Streitbuerger A, Hardes J, Heinemann M, Dirksen U.

Pediatr Blood Cancer. 2018 Dec;65(12):e27384. doi: 10.1002/pbc.27384. Epub 2018 Aug 7.

PMID:
30084137
8.

Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma.

Worch J, Ranft A, DuBois SG, Paulussen M, Juergens H, Dirksen U.

Pediatr Blood Cancer. 2018 Sep;65(9):e27251. doi: 10.1002/pbc.27251. Epub 2018 Jun 1.

PMID:
29856530
9.

Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92.

Whelan J, Hackshaw A, McTiernan A, Grimer R, Spooner D, Bate J, Ranft A, Paulussen M, Juergens H, Craft A, Lewis I.

Clin Sarcoma Res. 2018 Mar 30;8:6. doi: 10.1186/s13569-018-0093-y. eCollection 2018.

10.

Genome editing in Kluyveromyces and Ogataea yeasts using a broad-host-range Cas9/gRNA co-expression plasmid.

Juergens H, Varela JA, Gorter de Vries AR, Perli T, Gast VJM, Gyurchev NY, Rajkumar AS, Mans R, Pronk JT, Morrissey JP, Daran JG.

FEMS Yeast Res. 2018 May 1;18(3). doi: 10.1093/femsyr/foy012.

11.

Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial.

Frank JA, Ranft A, Paulussen M, Juergens H, Kruseova J, Bauer S, Niggli F, Reichardt P, Dirksen U.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26524. Epub 2017 Apr 24.

PMID:
28436593
12.

Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma.

Ranft A, Seidel C, Hoffmann C, Paulussen M, Warby AC, van den Berg H, Ladenstein R, Rossig C, Dirksen U, Rosenbaum D, Juergens H.

J Clin Oncol. 2017 May 20;35(15):1704-1712. doi: 10.1200/JCO.2016.70.6226. Epub 2017 Mar 29.

PMID:
28355116
13.

Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.

Thiel U, Wawer A, von Luettichau I, Bender HU, Blaeschke F, Grunewald TG, Steinborn M, Röper B, Bonig H, Klingebiel T, Bader P, Koscielniak E, Paulussen M, Dirksen U, Juergens H, Kolb HJ, Burdach SE.

Oncotarget. 2016 Oct 25;7(43):70959-70968. doi: 10.18632/oncotarget.10938.

14.

Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma.

Krumbholz M, Hellberg J, Steif B, Bäuerle T, Gillmann C, Fritscher T, Agaimy A, Frey B, Juengert J, Wardelmann E, Hartmann W, Juergens H, Dirksen U, Metzler M.

Clin Cancer Res. 2016 Sep 1;22(17):4356-65. doi: 10.1158/1078-0432.CCR-15-3028. Epub 2016 Jun 9. Erratum in: Clin Cancer Res. 2017 Jan 15;23 (2):610.

15.

Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group.

Foulon S, Brennan B, Gaspar N, Dirksen U, Jeys L, Cassoni A, Claude L, Seddon B, Marec-Berard P, Whelan J, Paulussen M, Streitbuerger A, Oberlin O, Juergens H, Grimer R, Le Deley MC.

Eur J Cancer. 2016 Jul;61:128-36. doi: 10.1016/j.ejca.2016.03.075. Epub 2016 May 10.

PMID:
27176931
16.

Management and Outcome of Ewing Sarcoma of the Head and Neck.

Grevener K, Haveman LM, Ranft A, van den Berg H, Jung S, Ladenstein R, Klco-Brosius S, Juergens H, Merks JH, Dirksen U.

Pediatr Blood Cancer. 2016 Apr;63(4):604-10. doi: 10.1002/pbc.25830. Epub 2015 Dec 24.

PMID:
26702872
17.

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O, Paulussen M, Picci P, Sundby Hall K, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein ML, Marec-Bérard P, Brennan B, Craft AW, Womer RB, Juergens H, Oberlin O.

J Clin Oncol. 2015 Sep 20;33(27):3036-46. doi: 10.1200/JCO.2014.59.5256. Epub 2015 Aug 24. Review.

PMID:
26304893
18.

Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.

van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group.

Eur J Cancer. 2015 Nov;51(16):2453-64. doi: 10.1016/j.ejca.2015.06.123. Epub 2015 Aug 10.

PMID:
26271204
19.

Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.

van Maldegem AM, Benson C, Rutkowski P, Blay JY, van den Berg H, Placzke J, Rasper M, Judson I, Juergens H, Dirksen U, Gelderblom H.

Pediatr Blood Cancer. 2015 Jan;62(1):40-4. doi: 10.1002/pbc.25230. Epub 2014 Sep 22.

PMID:
25251256
20.

Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to Non-Hodgkin-Lymphoma Berlin-Frankfurt-Münster protocols for systemic lymphoma.

Thorer H, Zimmermann M, Makarova O, Oschlies I, Klapper W, Lang P, von Stackelberg A, Fleischhack G, Worch J, Juergens H, Woessmann W, Reiter A, Burkhardt B.

Haematologica. 2014 Nov;99(11):e238-41. doi: 10.3324/haematol.2014.109553. Epub 2014 Aug 8. No abstract available.

21.

Diffuse hemorrhagic colitis in a patient with dyskeratosis congenita after nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Ehlert K, Rossig C, Groll AH, Beyna T, Froehlich B, Juergens H.

J Pediatr Hematol Oncol. 2015 Jan;37(1):e41-4. doi: 10.1097/MPH.0000000000000208.

PMID:
25000468
22.

Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.

Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le Teuff G, Michon J, Ladenstein R, Marec-Bérard P, van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U.

J Clin Oncol. 2014 Aug 10;32(23):2440-8. doi: 10.1200/JCO.2013.54.4833. Epub 2014 Jun 30.

PMID:
24982464
23.

Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.

Altvater B, Kailayangiri S, Theimann N, Ahlmann M, Farwick N, Chen C, Pscherer S, Neumann I, Mrachatz G, Hansmeier A, Hardes J, Gosheger G, Juergens H, Rossig C.

Cancer Immunol Immunother. 2014 Oct;63(10):1047-60. doi: 10.1007/s00262-014-1574-3. Epub 2014 Jun 28.

PMID:
24973179
24.

Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function.

Leuchte K, Altvater B, Hoffschlag S, Potratz J, Meltzer J, Clemens D, Luecke A, Hardes J, Dirksen U, Juergens H, Kailayangiri S, Rossig C.

Oncol Rep. 2014 Aug;32(2):845-52. doi: 10.3892/or.2014.3269. Epub 2014 Jun 13.

PMID:
24927333
25.

More on osteosarcoma and phylloides tumor.

Bielack SS, Hecker-Nolting S, Kevric M, Juergens H.

J Pediatr Hematol Oncol. 2015 Mar;37(2):158-9. doi: 10.1097/MPH.0000000000000197. No abstract available.

PMID:
24878621
26.

Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma.

Ahlmann M, Meyer C, Marschalek R, Burkhardt B, Koehler G, Klapper W, Juergens H, Rossig C.

Eur J Haematol. 2014 Oct;93(4):349-53. doi: 10.1111/ejh.12314. Epub 2014 Apr 28.

PMID:
24635731
27.

Osteosarcoma treatment - where do we stand? A state of the art review.

Luetke A, Meyers PA, Lewis I, Juergens H.

Cancer Treat Rev. 2014 May;40(4):523-32. doi: 10.1016/j.ctrv.2013.11.006. Epub 2013 Nov 27. Review.

PMID:
24345772
28.

Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.

Rossig C, Juergens H, Schrappe M, Moericke A, Henze G, von Stackelberg A, Reinhardt D, Burkhardt B, Woessmann W, Zimmermann M, Gadner H, Mann G, Schellong G, Mauz-Koerholz C, Dirksen U, Bielack S, Berthold F, Graf N, Rutkowski S, Calaminus G, Kaatsch P, Creutzig U.

Pediatr Blood Cancer. 2013 Oct;60(10):1574-81. doi: 10.1002/pbc.24598. Epub 2013 Jun 5. Review.

PMID:
23737479
29.

Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells.

Mueller SK, Altvater B, Chen C, Kailayangiri S, Ahlmann M, Dirksen U, Juergens H, Rossig C.

Oncol Rep. 2013 Jun;29(6):2348-54. doi: 10.3892/or.2013.2350. Epub 2013 Mar 19.

PMID:
23525469
30.

Genomic EWS-FLI1 fusion sequences in Ewing sarcoma resemble breakpoint characteristics of immature lymphoid malignancies.

Berger M, Dirksen U, Braeuninger A, Koehler G, Juergens H, Krumbholz M, Metzler M.

PLoS One. 2013;8(2):e56408. doi: 10.1371/journal.pone.0056408. Epub 2013 Feb 18.

31.

Long-term outcomes of hematopoietic stem cell transplantation for severe treatment-resistant autoimmune cytopenia in children.

Rabusin M, Snowden JA, Veys P, Quartier P, Dalle JH, Dhooge C, Di Bartolomeo P, Gonzalez-Vicent M, Gibson B, Iriondo A, Juergens H, Lisukov I, Messina C, Mialou V, Steward CG, Urban C, Renard M, Giurici N, Peters C, Badoglio M, Ronfani L, Dini G, Farge D, Saccardi R; European Group for Blood and Marrow Transplantation Autoimmune Diseases and Paediatric Disease Working Parties.

Biol Blood Marrow Transplant. 2013 Apr;19(4):666-9. doi: 10.1016/j.bbmt.2012.12.008. Epub 2012 Dec 16.

32.

Late graft failure in FA--case report and review of the literature.

Ehlert K, Groll AH, Rossig C, Fruehwald MC, Juergens H.

Pediatr Transplant. 2012 Dec;16(8):E360-3. doi: 10.1111/j.1399-3046.2012.01719.x. Epub 2012 May 23. Review.

PMID:
22616887
33.

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.

Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M, Dirksen U, Hardes J, Gosheger G, Juergens H, Rossig C.

Br J Cancer. 2012 Mar 13;106(6):1123-33. doi: 10.1038/bjc.2012.57. Epub 2012 Feb 28.

34.

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A.

J Clin Oncol. 2011 Dec 1;29(34):4534-40. doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24.

35.

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH.

J Clin Oncol. 2011 Dec 1;29(34):4541-7. doi: 10.1200/JCO.2010.34.0000. Epub 2011 Oct 24.

36.

New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.

Rossig C, Juergens H, Berdel WE.

Pediatr Hematol Oncol. 2011 Oct;28(7):539-55. doi: 10.3109/08880018.2011.613094. Review.

PMID:
21936619
37.

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.

Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C.

Cancer Immunol Immunother. 2012 Mar;61(3):385-96. doi: 10.1007/s00262-011-1111-6. Epub 2011 Sep 18.

PMID:
21928126
38.

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.

Chen CI, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S, Gerss J, Maecker HT, Berdel WE, Juergens H, Lee PP, Rossig C.

Leukemia. 2012 Mar;26(3):465-74. doi: 10.1038/leu.2011.239. Epub 2011 Sep 9.

PMID:
21904381
39.

Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML.

Stelljes M, Corbacioglu A, Schlenk RF, Döhner K, Frühwald MC, Rossig C, Ehlert K, Silling G, Müller-Tidow C, Juergens H, Döhner H, Berdel WE, Kienast J, Koschmieder S.

Leukemia. 2011 Jul;25(7):1209-10. doi: 10.1038/leu.2011.64. Epub 2011 Apr 1. No abstract available.

PMID:
21455213
40.

Childhood B-cell precursor acute lymphoblastic leukaemia in a patient with familial thrombocytopenia and RUNX1 mutation.

Linden T, Schnittger S, Groll AH, Juergens H, Rossig C.

Br J Haematol. 2010 Dec;151(5):528-30. doi: 10.1111/j.1365-2141.2010.08370.x. Epub 2010 Sep 29. No abstract available.

PMID:
20880108
41.

[Procedure guidelines for whole-body 18F-FDG PET and PET/CT in children with malignant diseases].

Franzius C, Stauss J, Pfluger T, Juergens KU, Kluge R, Amthauer H, Juergens H, Henze G, Stoever B, Hahn K.

Nuklearmedizin. 2010;49(6):225-33; quiz N60-1. doi: 10.3413/nukmed-0322. Epub 2010 Jul 9. German.

PMID:
20617279
42.

PET surveillance of patients with Ewing sarcomas of the trunk: Must the lower legs be included?

Vrachimis A, Dirksen U, Wessling J, Wenning C, Stegger L, Franzius C, Juergens H, Schober O, Weckesser M.

Nuklearmedizin. 2010;49(5):183-6. doi: 10.3413/nukmed-03131004. Epub 2010 Jul 9.

PMID:
20617278
43.

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo.

Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C.

Leukemia. 2010 May;24(5):1080-4. doi: 10.1038/leu.2010.38. Epub 2010 Mar 11. No abstract available.

PMID:
20220773
44.

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES).

Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, Burdach S, van den Berg H, Juergens H, Dirksen U.

Cancer. 2010 Jan 15;116(2):443-50. doi: 10.1002/cncr.24740.

45.

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, Campana D, Juergens H, Pule M, Rossig C.

Clin Cancer Res. 2009 Aug 1;15(15):4857-66. doi: 10.1158/1078-0432.CCR-08-2810. Epub 2009 Jul 28.

46.

A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.

Brinkrolf P, Landmeier S, Altvater B, Chen C, Pscherer S, Rosemann A, Ranft A, Dirksen U, Juergens H, Rossig C.

Int J Cancer. 2009 Aug 15;125(4):879-86. doi: 10.1002/ijc.24461.

47.

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Juergens H, Pule M, Rossig C.

Cancer Immunol Immunother. 2009 Dec;58(12):1991-2001. doi: 10.1007/s00262-009-0704-9. Epub 2009 Apr 10.

PMID:
19360406
48.

Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.

Landmeier S, Altvater B, Pscherer S, Juergens H, Varnholt L, Hansmeier A, Bollard CM, Moosmann A, Bisping G, Rossig C.

J Immunother. 2009 Apr;32(3):310-21. doi: 10.1097/CJI.0b013e31819b7c30.

49.

Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.

Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, Juergens H, Scheel-Walter HG, Bielack SS, Klingebiel T, Dickerhoff R, Kirsch S, Brecht I, Schmelzle R, Greulich M, Gadner H, Greiner J, Marky I, Treuner J, Koscielniak E.

J Clin Oncol. 2009 Mar 20;27(9):1446-55. doi: 10.1200/JCO.2007.15.0466. Epub 2009 Feb 17.

PMID:
19224858
50.

Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT.

Masjosthusmann K, Ehlert K, Eing BR, Roth J, Koehler G, Juergens H, Fruehwald M, Groll AH.

Bone Marrow Transplant. 2009 May;43(9):679-84. doi: 10.1038/bmt.2008.385. Epub 2008 Nov 24. Review.

PMID:
19029962

Supplemental Content

Loading ...
Support Center